AR079127A1 - Composiciones de daptomicina y metodos relacionados - Google Patents

Composiciones de daptomicina y metodos relacionados

Info

Publication number
AR079127A1
AR079127A1 ARP100104318A AR079127A1 AR 079127 A1 AR079127 A1 AR 079127A1 AR P100104318 A ARP100104318 A AR P100104318A AR 079127 A1 AR079127 A1 AR 079127A1
Authority
AR
Argentina
Prior art keywords
daptomycin
preparation
solid
sucrose
powdered
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Sandra O'connor
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of AR079127A1 publication Critical patent/AR079127A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP100104318 2009-11-23 2010-11-23 Composiciones de daptomicina y metodos relacionados AR079127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
AR079127A1 true AR079127A1 (es) 2011-12-28

Family

ID=44060422

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100104318 AR079127A1 (es) 2009-11-23 2010-11-23 Composiciones de daptomicina y metodos relacionados
ARP210102879A AR123846A2 (es) 2009-11-23 2021-10-19 Composición farmacéutica sólida liofilizada de daptomicina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210102879A AR123846A2 (es) 2009-11-23 2021-10-19 Composición farmacéutica sólida liofilizada de daptomicina

Country Status (33)

Country Link
US (3) US8835382B2 (enExample)
EP (2) EP2504353B2 (enExample)
JP (3) JP6041673B2 (enExample)
CN (3) CN104056250A (enExample)
AR (2) AR079127A1 (enExample)
AU (1) AU2010321531C1 (enExample)
BR (1) BR112012012406B1 (enExample)
CA (1) CA2781666C (enExample)
CL (2) CL2012001336A1 (enExample)
CO (1) CO6541585A2 (enExample)
CR (1) CR20120271A (enExample)
CY (1) CY1120854T1 (enExample)
DK (1) DK2504353T4 (enExample)
DO (1) DOP2012000140A (enExample)
EC (1) ECSP12011939A (enExample)
ES (1) ES2686331T5 (enExample)
FI (1) FI2504353T4 (enExample)
HR (1) HRP20181380T4 (enExample)
HU (1) HUE039967T2 (enExample)
IL (1) IL219891B (enExample)
LT (1) LT2504353T (enExample)
MX (1) MX2012005993A (enExample)
NZ (1) NZ600118A (enExample)
PE (2) PE20151717A1 (enExample)
PL (1) PL2504353T5 (enExample)
PT (1) PT2504353T (enExample)
RS (1) RS57566B2 (enExample)
RU (1) RU2607526C2 (enExample)
SG (1) SG10201407724YA (enExample)
SI (1) SI2504353T2 (enExample)
TR (1) TR201812823T4 (enExample)
TW (2) TWI606838B (enExample)
WO (1) WO2011063419A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
TWI606838B (zh) 2009-11-23 2017-12-01 庫比斯特製藥有限責任公司 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
KR20140037877A (ko) * 2011-05-26 2014-03-27 큐비스트 파마슈티컬즈 인코포레이티드 Cb-183,315 조성물 및 관련 방법
MX2014008390A (es) * 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
CA2881121A1 (en) * 2012-08-23 2014-03-27 Agila Specialties Private Limited Improved daptomycin injectable formulation
EP4066849B1 (en) * 2012-09-11 2025-03-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
ES2946600T3 (es) 2016-10-21 2023-07-21 Xellia Pharmaceuticals Aps Formulaciones líquidas de daptomicina
EP3675815A1 (en) 2017-08-31 2020-07-08 Xellia Pharmaceuticals ApS Daptomycin formulations
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
CN118873500A (zh) 2020-02-28 2024-11-01 埃克斯利亚制药有限公司 达托霉素制剂
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
CN1051200A (zh) 1984-10-09 1991-05-08 伊莱利利公司 制备抗菌素a-21978c复合物或因子的方法
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
DE69031730T2 (de) 1990-01-26 1998-04-23 Hoechst Ag Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (enExample) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
CA2133644C (en) 1992-04-20 2008-09-09 Alexander H. T. Chu Process for making vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
EP1674107B8 (en) 1998-09-25 2017-01-25 Cubist Pharmaceuticals LLC Use of daptomycin
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
CA2394350A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002056829A2 (en) * 2000-12-18 2002-07-25 Cubist Pharmaceuticals, Inc. Methods for preparing purified daptomycin
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
IL160169A0 (en) 2001-08-06 2004-07-25 Cubist Pharm Inc Nucleic acid molecules that encode a daptomycin non-ribosomal peptide synthetase and methods for the production thereof
DE60304992T2 (de) 2002-01-17 2007-01-18 Arkema France Supramolekularpolymere
IL166156A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Boroproline compound combination therapy
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
BRPI0607168A2 (pt) * 2005-02-14 2009-08-11 Venus Remedies Ltd terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
WO2006130629A2 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR101536781B1 (ko) * 2006-07-26 2015-07-14 산도즈 아게 카스포펀진 제형
EP2511844B1 (en) 2006-10-10 2015-08-12 XRpro Sciences, Inc. X-ray microscope
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
JP2010530846A (ja) * 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
EP2170362B1 (en) 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
US20100287884A1 (en) * 2007-10-25 2010-11-18 Sangita Seshadri Powder conditioning of unit dose drug packages
WO2009144739A1 (en) * 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
JP2013511522A (ja) 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
TWI606838B (zh) 2009-11-23 2017-12-01 庫比斯特製藥有限責任公司 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
CA2816077C (en) 2010-11-01 2021-08-10 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions comprising an emulsifier and dissolution aid
CA2822447C (en) 2010-12-23 2018-05-01 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法

Also Published As

Publication number Publication date
JP2017075186A (ja) 2017-04-20
RS57566B2 (sr) 2023-12-29
SG10201407724YA (en) 2014-12-30
RS57566B1 (sr) 2018-10-31
RU2012126076A (ru) 2013-12-27
LT2504353T (lt) 2018-09-25
ES2686331T5 (es) 2024-03-27
JP6088681B2 (ja) 2017-03-01
US20160030577A1 (en) 2016-02-04
BR112012012406B1 (pt) 2021-11-16
ES2686331T3 (es) 2018-10-17
HRP20181380T4 (hr) 2023-11-10
CL2012001336A1 (es) 2012-10-05
US20140364380A1 (en) 2014-12-11
PL2504353T3 (pl) 2018-11-30
HUE039967T2 (hu) 2019-02-28
DK2504353T3 (en) 2018-09-10
MX2012005993A (es) 2012-11-23
JP2016147874A (ja) 2016-08-18
JP2013511557A (ja) 2013-04-04
JP6041673B2 (ja) 2016-12-14
EP2504353A4 (en) 2014-04-02
EP2504353B1 (en) 2018-07-11
CN102712677B (zh) 2015-06-03
AU2010321531C1 (en) 2020-10-01
TR201812823T4 (tr) 2019-02-21
US9662397B2 (en) 2017-05-30
CL2015002412A1 (es) 2016-02-05
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
CN104056250A (zh) 2014-09-24
CO6541585A2 (es) 2012-10-16
PL2504353T5 (pl) 2023-11-20
SI2504353T1 (sl) 2018-10-30
CY1120854T1 (el) 2019-12-11
DK2504353T4 (da) 2023-11-20
US8835382B2 (en) 2014-09-16
US9138456B2 (en) 2015-09-22
EP3417849A1 (en) 2018-12-26
DOP2012000140A (es) 2012-10-30
EP2504353A2 (en) 2012-10-03
WO2011063419A2 (en) 2011-05-26
IL219891A0 (en) 2012-07-31
BR112012012406A2 (pt) 2019-12-03
ECSP12011939A (es) 2012-07-31
PE20121517A1 (es) 2012-11-26
CA2781666A1 (en) 2011-05-26
NZ600118A (en) 2014-08-29
TWI548414B (zh) 2016-09-11
TW201703791A (zh) 2017-02-01
SI2504353T2 (sl) 2023-11-30
CA2781666C (en) 2017-02-21
CR20120271A (es) 2012-08-01
CN102712677A (zh) 2012-10-03
AU2010321531A2 (en) 2014-10-30
US20120270772A1 (en) 2012-10-25
AU2010321531B2 (en) 2016-11-03
JP6239167B2 (ja) 2017-11-29
EP2504353B2 (en) 2023-09-13
AU2010321531A1 (en) 2012-06-14
WO2011063419A3 (en) 2011-10-13
FI2504353T4 (fi) 2023-11-30
IL219891B (en) 2018-01-31
AR123846A2 (es) 2023-01-18
PE20151717A1 (es) 2015-11-19
PT2504353T (pt) 2018-10-18
HRP20181380T1 (hr) 2018-10-19
RU2607526C2 (ru) 2017-01-10
CN108785654A (zh) 2018-11-13

Similar Documents

Publication Publication Date Title
AR079127A1 (es) Composiciones de daptomicina y metodos relacionados
PE20130217A1 (es) Composiciones farmaceuticas y metodos para su elaboracion
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
AR089673A1 (es) Formulacion de premezcla de dexmedetomidina
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
AU2013334740A8 (en) Stable, low viscosity antibody formulation
BRPI0818541B8 (pt) composição farmacêutica que compreende grânulos incluindo picossulfato de sódio e bicarbonato de potássio e seu processo para a preparação
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0913379B8 (pt) intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
MX346901B (es) Formulaciones de solucion intravenosa de posaconazol estabilizadas mediante beta-ciclodextrina sustituida.
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
PE20130063A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
AR123677A1 (es) Preparación y almacenamiento de formulaciones de rna liposomal adecuadas para terapia
BR112022003046A8 (pt) Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
MX356951B (es) Estabilizacion de fsh.
MA43686A (fr) Formulation liquide stable de gonadotrophines
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
AR094146A1 (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion
RU2012131162A (ru) Композиции вакцин
FI3554474T3 (fi) Mikafungiinikoostumuksia
PE20130064A1 (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos

Legal Events

Date Code Title Description
FC Refusal